BSE filing, NSE: ROSELABS. Summary written from the filing by ALFA Finder's alert engine.
Roselabs Finance Ltd: key numbers
- Share price
- ₹20.80
- Market cap
- ₹20.80 Cr
- Revenue (annual)
- ₹1.21 Cr
- Net profit (annual)
- ₹-0.31 Cr
- P/E (TTM)
- -65.9×Sector 33.7×
- Promoter holding
- 74.25%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Roselabs Finance Ltd
All →Roselabs Finance Q2 FY27 Results: Net Loss of ₹0.1 Cr, Loss Widens
Roselabs Finance Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Roselabs Finance Other Announcement
Roselabs Finance Ltd has submitted its quarterly shareholding pattern for the period ending September 30, 2026. This is a periodic regulatory compliance filing.
Roselabs Finance Board Meeting Date
Roselabs Finance Ltd intimated a Board meeting on October 22, 2026, to approve Q2 and H1 FY27 unaudited results. The trading window is closed for designated persons.
Roselabs Finance Acquisition
Roselabs Finance shareholders approved the Scheme of Merger with Lodha Developers Limited at an NCLT-convened meeting. The resolution was passed with the requisite majority.
Roselabs Finance Acquisition
Roselabs Finance Ltd has issued a notice for an NCLT-convened meeting of equity shareholders on October 09, 2026, to consider the proposed Scheme of Merger by Absorption.
Roselabs Finance Annual General Meeting
Roselabs Finance Limited concluded its 32nd AGM on August 27, 2026. Shareholders approved all resolutions, including the re-appointment of Mr. Raghava Reddy Balineni as Managing Director.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.